Institutional Investors Sentiment Indicator of Puma Biotechnology Inc (NYSE:PBYI) Falls in 2018 Q1

June 7, 2018 - By Henry Gaston

Sentiment for Puma Biotechnology Inc (NYSE:PBYI)

Puma Biotechnology Inc (NYSE:PBYI) institutional sentiment decreased to 1.14 in Q1 2018. Its down -0.51, from 1.65 in 2017Q4. The ratio fall, as 90 investment managers increased and started new holdings, while 79 sold and reduced equity positions in Puma Biotechnology Inc. The investment managers in our partner’s database reported: 34.13 million shares, down from 34.70 million shares in 2017Q4. Also, the number of investment managers holding Puma Biotechnology Inc in their top 10 holdings decreased from 5 to 4 for a decrease of 1. Sold All: 35 Reduced: 44 Increased: 69 New Position: 21.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. The company has market cap of $1.83 billion. The Company’s drug candidates include PB272 ) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). It currently has negative earnings. The firm also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.

The stock decreased 4.35% or $2.2 during the last trading session, reaching $48.35. About 243,843 shares traded. Puma Biotechnology, Inc. (NYSE:PBYI) has declined 33.50% since June 7, 2017 and is downtrending. It has underperformed by 46.07% the S&P500.

Analysts await Puma Biotechnology, Inc. (NASDAQ:PBYI) to report earnings on August, 8. They expect $-1.07 EPS, up 49.05 % or $1.03 from last year’s $-2.1 per share. After $-0.65 actual EPS reported by Puma Biotechnology, Inc. for the previous quarter, Wall Street now forecasts 64.62 % negative EPS growth.

Redmile Group Llc holds 2.88% of its portfolio in Puma Biotechnology, Inc. for 1.10 million shares. Partner Fund Management L.P. owns 2.03 million shares or 2.81% of their US portfolio. Moreover, Venbio Select Advisor Llc has 2.68% invested in the company for 825,368 shares. The New York-based Orbimed Advisors Llc has invested 2.23% in the stock. Partner Investment Management L.P., a California-based fund reported 27,154 shares.

Since January 1, 0001, it had 0 insider purchases, and 5 selling transactions for $1.46 million activity.

Puma Biotechnology, Inc. (NASDAQ:PBYI) Ratings Coverage

Ratings analysis reveals 63% of Puma Biotechnology’s analysts are positive. Out of 8 Wall Street analysts rating Puma Biotechnology, 5 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $70.0 while the high is $147.0. The stock’s average target of $97.75 is 102.17% above today’s ($48.35) share price. PBYI was included in 14 notes of analysts from January 22, 2018. The stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) earned “Buy” rating by Stifel Nicolaus on Wednesday, January 24. Bank of America maintained the shares of PBYI in report on Wednesday, January 24 with “Buy” rating. The firm has “Overweight” rating given on Wednesday, January 24 by JP Morgan. The rating was downgraded by Cowen & Co to “Market Perform” on Wednesday, January 24. The rating was maintained by Citigroup with “Buy” on Thursday, May 10. Stifel Nicolaus maintained it with “Buy” rating and $8700 target in Friday, May 11 report. The rating was maintained by Cowen & Co on Friday, March 2 with “Hold”. The company was downgraded on Thursday, April 12 by Barclays Capital. On Friday, March 9 the stock rating was maintained by Stifel Nicolaus with “Buy”. The firm has “Buy” rating by Credit Suisse given on Monday, January 22.

Another recent and important Puma Biotechnology, Inc. (NASDAQ:PBYI) news was published by which published an article titled: “Puma Biotech (PBYI) Highlights Interim Data of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab …” on June 04, 2018.

Puma Biotechnology, Inc. (NASDAQ:PBYI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: